Nasopharyngeal CancerNCT04340024
Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer Patients
An observational study of Nasopharyngeal Cancer and Prostate Cancer, run by National Cancer Centre, Singapore at 1 site in Singapore.
Trial summary
Patients with cancers that are sensitive to radiotherapy treatment and/or patients who have experienced severe acute/ late side effects to radiotherapy will be recruited to the study. Blood and/or matched tumour-normal tissue pairs will be collected. Read more about this study
- Who is it for?
- Ages 21 to 99 years
- Conditions the study is for
- Nasopharyngeal Cancer, Prostate Cancer, Other Cancer
- How many people
- 5,000 participants
- Where
- 1 siteSingapore
- Study dates
- 30 Sep 2015to 31 Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 99 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Participants will be recruited from patients of the study team when they attend their regular clinic visits or when they are admitted to the hospital. These are patients from NCCS.
Who may be able to join
- Patients with severe side effects from radiotherapy
- Patients with a type of cancer that is associated with sensitivity to radiotherapy
Who cannot join
- Age of patient must be between 21 (inclusive) and 99 (exclusive)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Melvin Chua, MD contact
Singapore1 site, 1 recruiting
- Recruiting
National Cancer Center Singapore
Singapore, 169690
About this study
Patients with cancers that are sensitive to radiotherapy treatment and/or patients who have experienced severe acute/ late side effects to radiotherapy will be recruited to the study. Blood and/or matched tumour-normal tissue pairs will be collected. Blood and/or tissue samples will be processed and studied for genetic and biochemical markers that have potential to be used for predicting sensitivity to radiation.
- Conditions
- Nasopharyngeal Cancer, Prostate Cancer, Other Cancer
- Keywords
- Radiotherapy, Biomarkers, Genomics, Immunomics, Precision medicine
- Medical subject headings
- Nasopharyngeal Neoplasms, Prostatic Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
To identify genes or molecular pathways that are associated with radiation sensitivity in blood and tissue samples
Whole exome sequencing, single nucleotide polymorphism (SNP) assays
Measured: Blood is taken at informed consent; tissue is from archived sample
Change in immune profile of blood and tissue after radiation
Mass cytometry using CyTOF technology will be used to detect the immune cell population
Measured: Blood is taken at informed consent; tissue is from archived sample
To identify proteins that are associated with radiation sensitivity in tissue samples
Immunohistochemistry will be used to detect protein expression
Measured: Tissue is from archived sample
To identify RNA expression pathways that are associated with radiation sensitivity in blood and tissue samples
RNA sequencing
Measured: Blood is taken at informed consent; tissue is from archived sample
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Apr 2020
- Study start30 Sep 2015
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Nasopharyngeal CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 5,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- National Cancer Centre, Singapore
- Sponsor type
- University, hospital or other
- Collaborators
- National Medical Research Council (NMRC), Singapore, Duke-NUS Graduate Medical School, Ferring Pharmaceuticals, ImmunoSCAPE, Decipher Biosciences
- Responsible party
- Sponsor
- Investigators
- Melvin Chua, MD, Principal investigator, National Cancer Centre, Singapore
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04340024
- Sponsor's protocol ID
- DISCLOSE
- Status last verified
- Jun 2025
- First submitted
- 26 Mar 2020
- Last updated
- 11 Jun 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer Patients
- ClinicalTrials.gov ID
- NCT04340024
- Acronym / sponsor ID
- DISCLOSE
- Conditions
- Nasopharyngeal Cancer, Prostate Cancer, Other Cancer
- Keywords
- Radiotherapy, Biomarkers, Genomics, Immunomics, Precision medicine
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 5,000 participants (estimated)
- Lead sponsor
- National Cancer Centre, SingaporeUniversity, hospital or other
- Collaborators
- National Medical Research Council (NMRC), Singapore, Duke-NUS Graduate Medical School, Ferring Pharmaceuticals, ImmunoSCAPE, Decipher Biosciences
- Study start
- 30 Sep 2015 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 9 Apr 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Patients with cancers that are sensitive to radiotherapy treatment and/or patients who have experienced severe acute/ late side effects to radiotherapy will be recruited to the study. Blood and/or matched tumour-normal tissue pairs will be collected. Blood and/or tissue samples will be processed and studied for genetic and biochemical markers that have potential to be used for predicting sensitivity to radiation.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 21 to 99 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Participants will be recruited from patients of the study team when they attend their regular clinic visits or when they are admitted to the hospital. These are patients from NCCS.
Key inclusion criteria (2 listed)
- Patients with severe side effects from radiotherapy
- Patients with a type of cancer that is associated with sensitivity to radiotherapy
Key exclusion criteria (1 listed)
- Age of patient must be between 21 (inclusive) and 99 (exclusive)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
To identify genes or molecular pathways that are associated with radiation sensitivity in blood and tissue samples
Time frame: Blood is taken at informed consent; tissue is from archived sample
Whole exome sequencing, single nucleotide polymorphism (SNP) assays
Change in immune profile of blood and tissue after radiation
Time frame: Blood is taken at informed consent; tissue is from archived sample
Mass cytometry using CyTOF technology will be used to detect the immune cell population
To identify proteins that are associated with radiation sensitivity in tissue samples
Time frame: Tissue is from archived sample
Immunohistochemistry will be used to detect protein expression
To identify RNA expression pathways that are associated with radiation sensitivity in blood and tissue samples
Time frame: Blood is taken at informed consent; tissue is from archived sample
RNA sequencing
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Jun 2025.
- Individual participant dataSharing planned: No
Related trials for Nasopharyngeal Cancer
RecruitingPhase 1/2
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
RecruitingPhase 2
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma
Active, not recruitingPhase 1
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
Breast Cancer, Ovarian Cancer
Not yet recruitingObservational study
Development and Validation of a Biopsy Decision Model for Nasopharyngeal Carcinoma Based on Serological Markers and Endoscopic Features
Nasopharyngeal Carcinoma (NPC)
RecruitingPhase 1/2
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Head and Neck Carcinoma, Adenoid Cystic Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Melvin Chua, MD contact
Melvin Chua, MD principal investigator
National Cancer Centre, Singapore
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Nasopharyngeal Cancer and Prostate Cancer, run by National Cancer Centre, Singapore at 1 site in Singapore.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 11 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Melvin Chua, MD (melvin.chua.l.k@singhealth.com.sg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To identify genes or molecular pathways that are associated with radiation sensitivity in blood and tissue samples (time frame: Blood is taken at informed consent; tissue is from archived sample). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jun 2025.